Home > Hematology > Dr. Elliott Vichinsky on Jadenu Get the Flash Player to see this player. Rate: (Click the stars to rate) Published on Mar 31, 2015 by MultiVu, Views: 2568 Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.